CELL BIOLOGY - IMMUNOLOGY - PATHOLOGY Calcium citrate ameliorates the progression of chronic renal injury

Gadola, Liliana; Noboa, Oscar; Márquez, María Natalia; Rodriguez, María José; Nin, Nicolás; Boggia, José; Ferreiro, Alejandro; García, Silvia; Ortega, Virginia; Musto, María Luisa; Ponte, Paolo; Sesser, Pablo; Pizarrosa, Carlos; Ravaglio, Silvana; Vallega, Ana
April 2004
Kidney International;Apr2004, Vol. 65 Issue 4, p1224
Academic Journal
Calcium citrate ameliorates the progression of chronic renal injury. Background. Metabolic acidosis is a consequence of chronic renal failure and it may produce bone demineralization, muscle proteolysis, and progression of chronic renal failure. The aim of this study was to evaluate the effects of correction of metabolic acidosis with calcium citrate in an experimental model of renal mass ablation. Methods. Wistar rats were subjected to 5/6 nephrectomy and were randomly assigned to one of 4 groups: nontreated (NFX); treated with calcium citrate (1.45 g/100 g feed) (NFX-CIT); treated with captopril (500 mg/L water) (NFX-CAP); or treated with both (NFX-CAP-CIT) during 1, 10, or 20 weeks. Body weight, systolic blood pressure, proteinuria, arterial bicarbonate concentration, urine citrate excretion, plasma calcium, and inulin clearance were measured. Histologic glomerular and tubulointerstitial damage scores were measured at 1, 10, and 20 weeks, and glomerular and tubular proliferating cell nuclear antigen (PCNA)-positive cells, α−smooth muscle actin, and desmin staining were studied by immunohistochemistry at 1 and 10 weeks. Results. The treated groups showed significantly less glomerular and tubulointerstitial cellular proliferation in the first week ( P < 0.05), less glomerular cell transdifferentiation and higher plasma bicarbonate at 10 weeks ( P < 0.05), as well as diminished histologic glomerular and tubulointerstitial damage scores at 20 weeks ( P < 0.05). Inulin clearances were higher ( P < 0.05), and urine protein excretion rates were lower ( P < 0.05) than in the NFX non-treated group, but arterial blood pressure was not significantly different in the NFX-CIT group. Conclusion. Calcium citrate slows the progression of chronic renal injury in the 5/6 NFX model. It improves metabolic acidosis and diminishes cell proliferation and transdifferentiation without changes in systolic blood pressure.


Related Articles

  • Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor-κB dependent. Wang, Yiping; Rangan, Gopala K.; Goodwin, Bryan; Tay, Yuet-Ching; Wang, Yang; Harris, David C.H. // Kidney International;May2000, Vol. 57 Issue 5, p2011 

    Lipopolysaccharide-induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor-κB dependent. Background. Endotoxin is an important factor in the development of acute renal failure related to infection and in acceleration of chronic nephritis. Lipopolysaccharide (LPS; the...

  • The contribution of acidosis to renal osteodystrophy. Bushinsky, David A. // Kidney International;Jun1995, Vol. 47 Issue 6, p1816 

    Discusses the contribution of acidosis to renal osteodystrophy. Types of bone disorders observed in patients with end-stage renal disease; Increase in the serum parathyroid hormone brought by the declining renal function; Role of cellular activity in proton-mediated bone resorption; Cause of...

  • Acidosis, not azotemia, stimulates branched-chain, amino acid catabolism in uremic rats. Hara, Yoko; May, Robert C.; Kelly, Ralph A.; Mitch, William E. // Kidney International;Dec1987, Vol. 32 Issue 6, p808 

    To investigate branched-chain, amino acid metabolism (BCAA) in muscle in chronic renal failure (CRF). we studied nits with moderately severe uremia (PUN 110 ∼ mg/dl) and spontaneous metabolic acidosis (bicarbonate, 19 ± 1 mEq/liter). Plasma BCAA levels in CRF compared to pair-fed control...

  • Circulating biochemical markers of bone remodeling in uremic patients. Ureña, Pablo; de Vernejoul, Marie-Christine; Ureña, P; De Vernejoul, M C // Kidney International;Jun1999, Vol. 55 Issue 6, p2141 

    Chronic renal failure is often associated with bone disorders, including secondary hyperparathyroidism, aluminum-related low-turnover bone disease, osteomalacia, adynamic osteopathy, osteoporosis, and skeletal beta2-microglobulin amyloid deposits. In spite of the enormous progress made during...

  • Low bone turnover in patients with renal failure. Couttenye, Marie Madeleine; D'Haese, Patrick C.; Verschoren, Wim J.; Behets, Geert J.; Schrooten, Iris; De Broe, Marc E. // Kidney International Supplement;Dec1999, Issue 73, pS-70 

    Evaluates the low bone turnover in patients with renal failure. Low Number of osteoblast with normal or reduced numbers of osteoblasts; Contribution of various types of renal osteodystrophy to the spectrum of the histological picture in renal failure patients; Effects of secondary...

  • Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Meves, Katia R.; Graciolli, Fabiana G.; Dos Reis, Luciene M.; Pasqualucci, Carlos A.; Moysés, Rosa M. A.; Jorgetti, Vanda // Kidney International;Dec2004, Vol. 66 Issue 6, p2237 

    Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.Background. Hyperphosphatemia and disturbances in calcium or parathyroid hormone (PTH) metabolism contribute to the high incidence of cardiovascular disease and renal...

  • Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Damment, Stephen; Secker, Roger; Shen, Victor; Lorenzo, Victor; Rodriguez, Mariano // Nephrology Dialysis Transplantation;Jun2011, Vol. 26 Issue 6, p1803 

    Background. Lanthanum carbonate (FOSRENOL®, Shire Pharmaceuticals) is an effective non-calcium, non-resin phosphate binder for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). In this study, we used a rat model of chronic renal failure (CRF) to examine the...

  • Expression of bone type 1 PTH receptor in rats with chronic renal failure. Kuwahara, Michio; Inoshita, Seiji; Nakano, Yukiko; Terada, Yoshio; Takano, Yoshiro; Sasaki, Sei // Clinical & Experimental Nephrology;Mar2007, Vol. 11 Issue 1, p34 

    Some researchers have speculated that a decrease in bone type 1 PTH receptor (PTH1R) may be among the causes of “skeletal resistance” in chronic renal failure (CRF). Indeed, the down-regulation of PTH1R mRNA has been identified in uremic bones. However, few studies have identified...

  • The effects of intraoperative normal saline versus lactated ringer solution on clinical outcomes and laboratory findings in renal transplant patients. Nuraei, Navid; Khajenouri, Reza; Soleimani, Mohammad; Dabbagh, Ali // Tehran University Medical Journal;Jul2010, Vol. 68 Issue 4, p243 

    Background: Patients with chronic renal disease, if not treated appropriately, will be usually terminated into an irreversible stage known as End Stage Renal Disease (ESRD), the final stage of kidney disease. End stage renal disease patients cannot excrete the appropriately potassium ion through...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics